EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

IgA Vasculitis (Henoch–Schönlein Purpura): An Update on Treatment

Santos Castañeda iD, Patricia Quiroga-Colina, Paz Floranes, Miren Uriarte-Ecenarro, Cristina Valero-Martínez, Esther F Vicente-Rabaneda, Miguel A González-Gay iD

Journal of Clinical Medicine · 04.11.2024 · 13 (21) · 6621

DOI: 10.3390/jcm13216621 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 04.11.2024. Verfasst von Santos Castañeda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Division, H. Universitario La Princesa, IIS-Princesa, 28006 Madrid, Spain. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FOREUM (Program Foundation for Research in Rheumatology), “Instituto de Salud Carlos III” (ISCIII) (Spain).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

IgA vasculitis (IgAV), previously named as Henoch–Schönlein purpura, is the most frequent systemic vasculitis in children. In adults, IgAV is less common although it is associated with more severe disease. In fact, the frequency of glomerulonephritis (referred to as IgAV nephritis) in adults is higher than in children and tends to present more severely, with around 10–30% of those affected eventually progressing to end-stage renal disease. In this review, we describe the pathophysiology, main clinical features, diagnosis of the disease, and latest clinical data regarding IgAV therapy.

Methods

A narrative literature review, primarily based on articles published in PubMed, was conducted. In addition to discussing the main aspects of glucocorticoids and conventional disease-modifying drugs used in the management of IgAV, this review focuses on the latest information reported regarding biologics and potential future therapies.

Results

Glucocorticoids are the first-line therapy for IgAV, especially in adults with severe manifestations. Colchicine, dapsone, and methotrexate can be useful for controlling minor manifestations. Several immunomodulatory agents, such as cyclosporine A, tacrolimus, and mycophenolate mofetil, have shown favorable results as glucocorticoid-sparing agents. Leflunomide has shown promising results but requires further study. The use of rituximab has demonstrated efficacy in reducing relapse frequency, lowering the cumulative glucocorticoid burden, and achieving long-term remission of the disease in children and adults with IgAV. Immunoglobulins and plasma exchange therapy can also be useful in difficult and life-threatening situations. Other potential therapies with encouraging results include TRF-budesonide, B-cell-directed therapy, B-cell-depleting agents, sodium–glucose cotransporter-2 inhibitors, endothelin receptor antagonists, and complement pathway inhibitors.

Conclusions

Glucocorticoids are the first-line therapy for IgAV, especially in adults with severe manifestations. The role of various immunomodulatory therapies, such as calcineurin inhibitors and mycophenolate mofetil, remains promising, while rituximab reduces the long-term side effects of glucocorticoids and can help achieve disease remission. Other potential therapies with encouraging results require further research.

Schlagwörter

Stichwörter der Autor:innen

Henoch–Schönlein purpuraIgA vasculitisIgA vasculitis nephritiscyclophosphamidecyclosporine Aexperimental therapiesglucocorticoidsimmunoglobulinsmycophenolate mofetilplasma exchangerituximabtacrolimus

Autor:innen und Institutionen

  • Rheumatology Division, H. Universitario La Princesa, IIS-Princesa, 28006 Madrid, Spain.
  • Department of Medicine, Universidad Autónoma de Madrid (UAM), 28049 Madrid, Spain.
  • Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, 39011 Santander, Spain.
  • Rheumatology Division, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain.
  • Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa.

ORCID-Profile: Santos Castañeda, Miguel A González-Gay

Förderung

  • FOREUM (Program Foundation for Research in Rheumatology)
  • “Instituto de Salud Carlos III” (ISCIII) (Spain)

Zitieren

APA

Castañeda, S., Quiroga-Colina, P., Floranes, P., Uriarte-Ecenarro, M., Valero-Martínez, C., Vicente-Rabaneda, E. F., & González-Gay, M. A. (2024). IgA Vasculitis (Henoch–Schönlein Purpura): An Update on Treatment. Journal of Clinical Medicine, 13(21), 6621. https://doi.org/10.3390/jcm13216621

Vancouver

Castañeda S, Quiroga-Colina P, Floranes P, Uriarte-Ecenarro M, Valero-Martínez C, Vicente-Rabaneda EF, et al. IgA Vasculitis (Henoch–Schönlein Purpura): An Update on Treatment. Journal of Clinical Medicine. 2024;13(21):6621. doi:10.3390/jcm13216621

BibTeX
@article{Castaeda2024,
  author = {Castañeda, Santos and Quiroga-Colina, Patricia and Floranes, Paz and Uriarte-Ecenarro, Miren and Valero-Martínez, Cristina and Vicente-Rabaneda, Esther F and González-Gay, Miguel A},
  title = {IgA Vasculitis (Henoch–Schönlein Purpura): An Update on Treatment},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {21},
  pages = {6621},
  doi = {10.3390/jcm13216621}
}
Kostenlos starten →